Literature DB >> 30822683

Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.

Taisuke Yagi1, Yoshifumi Baba1, Kazuo Okadome1, Yuki Kiyozumi1, Yukiharu Hiyoshi1, Takatsugu Ishimoto1, Masaaki Iwatsuki1, Yuji Miyamoto1, Naoya Yoshida1, Masayuki Watanabe2, Yoshihiro Komohara3, Hideo Baba4.   

Abstract

INTRODUCTION: Tumour-associated macrophages (TAMs) in tumour microenvironments promote cancer cell proliferation, immunosuppression and angiogenesis, leading to tumour growth and metastasis. TAMs have become increasingly recognised as a cancer therapy target, such as in combination therapy with an immunity checkpoint inhibitor. However, the clinical and prognostic features of TAMs, and the relationship between TAMs and programmed death ligand 1 (PD-L1), remain unexplored in oesophageal cancer.
METHODS: Using a non-biased database of 305 resected oesophageal cancer preparations, we evaluated the expression of two M2-like macrophage markers (CD163 and CD204) and PD-L1 on tumour cells by immunostaining. Through in vitro assays, we examined how TAMs influence phenotypic malignancy and PD-L1 expression.
RESULTS: High density of CD163 (n = 160) or CD204 (n = 146) was associated with significantly worse overall survival than low expression (log rank P = 0.0025 and 0.018 for CD163 and CD204, respectively). The prognostic effect of TAMs was not significantly modified by any clinical factors (P > 0.05 for all interactions). High TAM density was significantly associated with increased PD-L1 expression. In in vitro assays, cell invasion and migration ability were significantly more upregulated in oesophageal cancer cell lines cocultured with activated macrophages than in control cell lines. Coculture with activated macrophages elevated the PD-L1 expression in cancer cells.
CONCLUSIONS: High TAM density in oesophageal cancer tissues was associated with shorter survival, suggesting a prognostic biomarker role for TAMs. TAMs also increase PD-L1 expression in tumour cells. Given the significant interest in cancer immunotherapies targeting TAMs and PD-L1, the current findings should have considerable clinical implications.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Oesophageal cancer; PD-L1; Prognosis; TAM

Mesh:

Substances:

Year:  2019        PMID: 30822683     DOI: 10.1016/j.ejca.2019.01.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  36 in total

1.  Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.

Authors:  Binita Chakraborty; Jovita Byemerwa; Jonathan Shepherd; Corinne N Haines; Robert Baldi; Weida Gong; Wen Liu; Debarati Mukherjee; Sandeep Artham; Felicia Lim; Yeeun Bae; Olivia Brueckner; Kendall Tavares; Suzanne E Wardell; Brent A Hanks; Charles M Perou; Ching-Yi Chang; Donald P McDonnell
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 14.808

Review 2.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 3.  The tumour immune microenvironment in oesophageal cancer.

Authors:  Maria Davern; Noel E Donlon; Margaret R Dunne; Robert Power; Conall Hayes; Ross King; John V Reynolds
Journal:  Br J Cancer       Date:  2021-04-26       Impact factor: 7.640

4.  Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.

Authors:  Li Zhang; Buyi Zhang; Zhangqi Dou; Jiawei Wu; Yasaman Iranmanesh; Biao Jiang; Chongran Sun; Jianmin Zhang
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

Review 5.  Strategies to Interfere with Tumor Metabolism through the Interplay of Innate and Adaptive Immunity.

Authors:  Javier Mora; Christina Mertens; Julia K Meier; Dominik C Fuhrmann; Bernhard Brüne; Michaela Jung
Journal:  Cells       Date:  2019-05-11       Impact factor: 6.600

Review 6.  Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.

Authors:  Yumi Kambayashi; Taku Fujimura; Takanori Hidaka; Setsuya Aiba
Journal:  Front Med (Lausanne)       Date:  2019-07-31

Review 7.  Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers.

Authors:  Ross King; Conall Hayes; Claire L Donohoe; Margaret R Dunne; Maria Davern; Noel E Donlon
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

8.  Effect of surface mannosylation on the cytotoxicity and cellular uptake of stearoyl gemcitabine-incorporated, acid-sensitive micelles.

Authors:  Riyad F Alzhrani; Haiyue Xu; Solange A Valdes; Youssef W Naguib; Zhengrong Cui
Journal:  Colloid Interface Sci Commun       Date:  2021-06-23

Review 9.  Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases.

Authors:  Maria K Skytthe; Jonas Heilskov Graversen; Søren K Moestrup
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

10.  Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors:  Shen-Jun Yuan; Yong-Hong Xu; Chao Wang; Hui-Chao An; Hua-Zhen Xu; Ke Li; Naoki Komatsu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2019-10-17       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.